O

Obio Technology Shanghai Corp Ltd
SSE:688238

Watchlist Manager
Obio Technology Shanghai Corp Ltd
SSE:688238
Watchlist
Price: 5.29 CNY -3.11% Market Closed
Market Cap: 3.4B CNY
Have any thoughts about
Obio Technology Shanghai Corp Ltd?
Write Note

Obio Technology Shanghai Corp Ltd
Change in Working Capital

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Obio Technology Shanghai Corp Ltd
Change in Working Capital Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Change in Working Capital CAGR 3Y CAGR 5Y CAGR 10Y
O
Obio Technology Shanghai Corp Ltd
SSE:688238
Change in Working Capital
-ÂĄ168m
CAGR 3-Years
-48%
CAGR 5-Years
-39%
CAGR 10-Years
N/A
WuXi AppTec Co Ltd
SSE:603259
Change in Working Capital
-ÂĄ11.7B
CAGR 3-Years
-15%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Change in Working Capital
-ÂĄ7B
CAGR 3-Years
-25%
CAGR 5-Years
-29%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Change in Working Capital
ÂĄ3.2B
CAGR 3-Years
13%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Change in Working Capital
-ÂĄ3.1B
CAGR 3-Years
-24%
CAGR 5-Years
-21%
CAGR 10-Years
-32%
W
WuXi XDC Cayman Inc
HKEX:2268
Change in Working Capital
-ÂĄ142.5m
CAGR 3-Years
-47%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Obio Technology Shanghai Corp Ltd
Glance View

Market Cap
3.4B CNY
Industry
Life Sciences Tools & Services

Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai and currently employs 631 full-time employees. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.

Intrinsic Value
4.56 CNY
Overvaluation 14%
Intrinsic Value
Price
O

See Also

What is Obio Technology Shanghai Corp Ltd's Change in Working Capital?
Change in Working Capital
-168m CNY

Based on the financial report for Dec 31, 2023, Obio Technology Shanghai Corp Ltd's Change in Working Capital amounts to -168m CNY.

What is Obio Technology Shanghai Corp Ltd's Change in Working Capital growth rate?
Change in Working Capital CAGR 5Y
-39%

Over the last year, the Change in Working Capital growth was -53%. The average annual Change in Working Capital growth rates for Obio Technology Shanghai Corp Ltd have been -48% over the past three years , -39% over the past five years .

Back to Top